Srpt nasdaq
Hailshadow. Sarepta Therapeutics (NASDAQ:SRPT) is a large (~$14 billion market cap) biopharmaceutical company that markets 3 RNA-targeted products for Duchenne muscular dystrophy (DMD) patients.In ...Insiders have sold a total of 15,858 Sarepta Therapeutics shares in the last 24 months for a total of $1,695,111.36 sold. Which members of congress are trading Sarepta Therapeutics? Josh Gottheimer (D-NJ) and Daniel S. Goldman (D-NY) have bought shares of Sarepta Therapeutics in the last year totaling $48,500.Net product revenue for the first quarter of 2022 from our PMO exon skipping franchise was $188.8 million compared to $124.9 million for the same period of 2021. For the first quarter of 2022 ...
Did you know?
May 11, 2023 · Fintel reports that on May 15, 2023, UBS maintained coverage of Sarepta Therapeutics (NASDAQ:SRPT) with a Buy recommendation.. Analyst Price Forecast Suggests ∞% Upside. As of May 11, 2023, the ... Dec 1, 2023 · In the previous quarter, Sarepta Therapeutics (NASDAQ:SRPT) reported $0.37 earnings per share (EPS) to beat the analysts' consensus estimate of ($1.63) by $2.00. Learn more on analysts' earnings estimate vs. SRPT's actual earnings. SRPT SRPT AFTER HOURS QUOTE SRPT LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...
Interactive Chart for Sarepta Therapeutics, Inc. (SRPT), analyze all the data with a huge range of indicators.About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.12 Nis 2023 ... Hartaj Singh, Managing Director at Opco, recommends Astria Therapeutics (NASDAQ:ATXS), Biomea (NASDAQ:BMEA) and Sarepta (NASDAQ:SRPT)Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Call Transcript November 1, 2023 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.46, expectations were $-1.63.Apr 24, 2023 · Fintel reports that on May 3, 2023, RBC Capital maintained coverage of Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform recommendation.. Analyst Price Forecast Suggests 36.96% Upside. As of ...
Interactive Chart for Sarepta Therapeutics, Inc. (SRPT), analyze all the data with a huge range of indicators.Nov 6, 2023 · Barry was up about 5.5% on the purchase at the high point of today's trading session, with SRPT trading as high as $83.11 at last check today. VIDEO: Monday 11/6 Insider Buying Report: RELY, SRPT Nov 29, 2023 · SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT GlobeNewswire Nov 2, 2023 1:37am ….
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Srpt nasdaq. Possible cause: Not clear srpt nasdaq.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Purchase Date: November 3 Richard Barry, who is a director at Sarepta Therapeutics, Inc. (NASDAQ:SRPT), bough t 50,000 shares of the company at $78 ...Fintel reports that on October 31, 2023, Needham maintained coverage of Sarepta Therapeutics (NASDAQ:SRPT) with a Buy recommendation.. Analyst Price Forecast Suggests 71.45% Upside. As of October ...
SRPT SRPT AFTER HOURS QUOTE SRPT LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...View real-time SRPT stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal. Sarepta Therapeutics Inc. shares SRPT, +0.77% dropped more than 40% premarket on Tuesday after the company said a trial of its gene therapy for Duchenne muscular dystrophy fell short of its main goal. 26 days ago - Market Watch.
we stock forecast SRPT Nasdaq Global Select Market. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).Dec 2, 2023 · Current Trading Halts. Nov 30, 2023. Halt times displayed are Eastern Time (ET). updating.... Pause Threshold Price. If a security is subject to a Trading Pause, the Pause Threshold Price field will contain the reference threshold price that deviates 10% from a print on the Consolidated Tape that is last sale eligible as compared to every print ... nysearca vgt compareiwb etf Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. Fintel reports that on May 15, 2023, UBS maintained coverage of Sarepta Therapeutics (NASDAQ:SRPT) with a Buy recommendation.. Analyst Price Forecast Suggests ∞% Upside. As of May 11, 2023, the ... scansource inc Fintel reports that on October 31, 2023, RBC Capital maintained coverage of Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform recommendation.. Analyst Price Forecast Suggests 49.39% Upside. As ...Nov 23, 2023 · Shares of NASDAQ:SRPT opened at $83.77 on Tuesday. The stock has a market cap of $7.84 billion, a PE ratio of -10.70 and a beta of 0.96. The company’s fifty day moving average is $104.82 and its 200 day moving average is $114.01. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89. futures trading indicatorsbest healthcare plans for familieswhat reits pay monthly dividends SRPT SRPT AFTER HOURS QUOTE SRPT LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... iphone 15 price increase Feb 28, 2023 · CAMBRIDGE, Mass., February 28, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter ... Sarepta Therapeutics (NASDAQ: SRPT) stock is sliding lower on Friday after the company announced an advisory committee meeting with the Food and Drug Administration (FDA).. According to a press ... is microsoft a buymortgage broker bankruptcybenz japan The decrease is primarily due to a decrease in our manufacturing expenses, partially offset by increases in clinical trial expenses. On a non-GAAP basis, R&D expenses were $163.9 million for the ...